PMID- 22751596
OWN - NLM
STAT- MEDLINE
DCOM- 20121017
LR  - 20151119
IS  - 0380-0903 (Print)
IS  - 0380-0903 (Linking)
VI  - 89
DP  - 2012 Jul
TI  - Soluble biomarkers may differentiate psoriasis from psoriatic arthritis.
PG  - 65-6
LID - 10.3899/jrheum.120247 [doi]
AB  - Patients with psoriatic arthritis (PsA) have a higher inflammatory burden and 
      poorer quality of life compared to patients with psoriasis without PsA. Early 
      identification of PsA may prevent joint damage progression and improve quality of 
      life. Soluble biomarkers have the potential to be useful for screening patients 
      with psoriasis for underlying PsA so that appropriate referral to a 
      rheumatologist is made. Pilot studies have shown that C-reactive protein, 
      interleukin 6, cartilage oligomeric matrix protein (COMP), Dickkopf-1, and 
      macrophage-colony stimulating factor may differentiate PsA from psoriasis without 
      PsA. Compared with controls, increased serum levels of receptor activator of 
      nuclear factor-kappaB ligand, tumor necrosis factor superfamily member 14, matrix 
      metalloproteinase-3 (MMP-3), and COMP are independently associated with psoriatic 
      disease. Increased levels of high-sensitivity CRP (hsCRP), osteoprotegerin (OPG), 
      MMP-3, and the ratio of C-propeptide of type II collagen (CPII) to collagen 
      fragment neoepitopes Col2-3/4 C(long mono) (C2C) are independently associated 
      with PsA. A combination of hsCRP, OPG, MMP-3, and the ratio CPII of C2C was able 
      to distinguish patients with PsA from those with psoriasis alone in a 
      receiver-operating characteristic curve analysis, with area under the curve 
      0.904. Therefore, a combination of the above biomarkers may at least have a role 
      in screening patients with psoriasis for PsA. These findings need to be validated 
      in prospective studies.
FAU - Chandran, Vinod
AU  - Chandran V
AD  - Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 
      University Health Network, Toronto, Ontario M5T 2S8, Canada. 
      vchandra@uhnresearch.ca
LA  - eng
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Canada
TA  - J Rheumatol Suppl
JT  - The Journal of rheumatology. Supplement
JID - 7806058
RN  - 0 (Biomarkers)
RN  - 0 (Osteoprotegerin)
RN  - 0 (Peptide Fragments)
RN  - 0 (Procollagen)
RN  - 0 (TNFRSF11B protein, human)
RN  - 0 (procollagen type II carboxy-terminal peptide)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Arthritis, Psoriatic/blood/*diagnosis
MH  - Biomarkers/*blood
MH  - C-Reactive Protein/analysis
MH  - Diagnosis, Differential
MH  - Humans
MH  - Matrix Metalloproteinase 3/blood
MH  - Osteoprotegerin/blood
MH  - Peptide Fragments/blood
MH  - Predictive Value of Tests
MH  - Procollagen/blood
MH  - Prognosis
MH  - Psoriasis/blood/*diagnosis
MH  - ROC Curve
EDAT- 2012/07/04 06:00
MHDA- 2012/10/18 06:00
CRDT- 2012/07/04 06:00
PHST- 2012/07/04 06:00 [entrez]
PHST- 2012/07/04 06:00 [pubmed]
PHST- 2012/10/18 06:00 [medline]
AID - 89/0/65 [pii]
AID - 10.3899/jrheum.120247 [doi]
PST - ppublish
SO  - J Rheumatol Suppl. 2012 Jul;89:65-6. doi: 10.3899/jrheum.120247.